{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:58:59Z","timestamp":1788447539966,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"NOVARTis PHARMA (FR)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12882-016-0336-1","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T13:07:01Z","timestamp":1474463221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Blood pressure and proteinuria control remains a challenge in patients with type 2 diabetes mellitus and chronic kidney disease: experience from the prospective observational ALICE-PROTECT study"],"prefix":"10.1186","volume":"17","author":[{"given":"Jean-Michel","family":"Halimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Dussol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Fauvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Qu\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Fiquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,21]]},"reference":[{"key":"336_CR1","unstructured":"International Diabetes Federation. Diabetes Atlas Update 2012. 5th ed. Belgium: International Diabetes Federation; 2012."},{"key":"336_CR2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.diabet.2014.11.007","volume":"41","author":"E Eschwege","year":"2014","unstructured":"Eschwege E, Basdevant A, Crine A, Moisan C, Charles MA. Type 2 diabetes mellitus in France in 2012: results from the ObEpi survey. Diabetes Metab. 2014;41:55\u201361.","journal-title":"Diabetes Metab"},{"key":"336_CR3","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med. 2014;370:1514\u201323.","journal-title":"N Engl J Med"},{"key":"336_CR4","doi-asserted-by":"crossref","unstructured":"Lassalle M, Ayav C, Frimat L, Jacquelinet C, Couchoud C. The essential of 2012 results from the French Renal Epidemiology and Information Network (REIN) ESRD registry. Nephrol Ther. 2014.","DOI":"10.1016\/j.nephro.2014.08.002"},{"key":"336_CR5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2369-13-87","volume":"13","author":"G Coll-de-Tuero","year":"2012","unstructured":"Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A, et al. Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area. BMC Nephrol. 2012;13:87.","journal-title":"BMC Nephrol"},{"key":"336_CR6","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.clinthera.2009.10.020","volume":"31","author":"CE Koro","year":"2009","unstructured":"Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31:2608\u201317.","journal-title":"Clin Ther"},{"key":"336_CR7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMcp011773","volume":"346","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145\u201351.","journal-title":"N Engl J Med"},{"key":"336_CR8","doi-asserted-by":"crossref","first-page":"e110535","DOI":"10.1371\/journal.pone.0110535","volume":"9","author":"LA Szczech","year":"2014","unstructured":"Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One. 2014;9:e110535.","journal-title":"PLoS One"},{"key":"336_CR9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s00125-014-3160-9","volume":"57","author":"FG Assogba","year":"2014","unstructured":"Assogba FG, Couchoud C, Hannedouche T, et al. Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007\u20132011. Diabetologia. 2014;57:718\u201328.","journal-title":"Diabetologia"},{"key":"336_CR10","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662\u201373.","journal-title":"Lancet"},{"key":"336_CR11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807\u201314.","journal-title":"Lancet"},{"key":"336_CR12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225\u201332.","journal-title":"Kidney Int"},{"key":"336_CR13","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1523-1755.2004.00925.x","volume":"66","author":"K Rossing","year":"2004","unstructured":"Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596\u2013605.","journal-title":"Kidney Int"},{"key":"336_CR14","doi-asserted-by":"crossref","unstructured":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253\u2013259.","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"336_CR15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"336_CR16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603\u201315.","journal-title":"JAMA"},{"key":"336_CR17","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433\u201346.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"336_CR18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1262-3636(11)70961-2","volume":"37","author":"F Bonnet","year":"2011","unstructured":"Bonnet F, Gauthier E, Gin H, et al. Expert consensus on management of diabetic patients with impairment of renal function. Diabetes Metab. 2011;37 Suppl 2:S1\u201325.","journal-title":"Diabetes Metab"},{"key":"336_CR19","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159\u2013219.","journal-title":"Eur Heart J"},{"key":"336_CR20","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(Suppl 1):S11-S66.","DOI":"10.2337\/dc13-S011"},{"key":"336_CR21","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","volume":"123","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799\u2013810. 9.","journal-title":"Circulation"},{"key":"336_CR22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ancard.2013.04.009","volume":"62","author":"J Blacher","year":"2013","unstructured":"Blacher J, Halimi JM, Hanon O, et al. Management of arterial hypertension in adults: 2013 guidelines of the French Society of Arterial Hypertension. Ann Cardiol Angeiol (Paris). 2013;62:132\u20138.","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"336_CR23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"336_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.diabres.2015.01.029","volume":"108","author":"D Joly","year":"2015","unstructured":"Joly D, Choukroun G, Combe C, et al. Glycemic control according to glomerular filtration rate in patients with type 2 diabetes and overt nephropathy: a prospective observational study. Diabetes Res Clin Pract. 2015;108:120\u20137.","journal-title":"Diabetes Res Clin Pract"},{"key":"336_CR25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/ki.2010.292","volume":"78","author":"G Bakris","year":"2010","unstructured":"Bakris G, Vassalotti J, Ritz E, et al. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010;78:726\u201336.","journal-title":"Kidney Int"},{"key":"336_CR26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/jch.12095","volume":"15","author":"N Desai","year":"2013","unstructured":"Desai N, Madhavankutty SV, Hunter K, McFadden C. Prevalence of true therapeutic inertia in blood pressure control in an academic chronic kidney disease clinic. J Clin Hypertens (Greenwich). 2013;15:375\u20139.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"336_CR27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1053\/j.ajkd.2005.02.015","volume":"45","author":"MJ Andersen","year":"2005","unstructured":"Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis. 2005;45:994\u20131001.","journal-title":"Am J Kidney Dis"},{"key":"336_CR28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.ki.5000081","volume":"69","author":"R Agarwal","year":"2006","unstructured":"Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69:406\u201311.","journal-title":"Kidney Int"},{"key":"336_CR29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/HYPERTENSIONAHA.108.115154","volume":"53","author":"V Pogue","year":"2009","unstructured":"Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009;53:20\u20137.","journal-title":"Hypertension"},{"key":"336_CR30","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D Zeeuw de","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309\u201320.","journal-title":"Kidney Int"},{"key":"336_CR31","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","volume":"18","author":"WB Eijkelkamp","year":"2007","unstructured":"Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"336_CR32","first-page":"779","volume":"370","author":"LF Fried","year":"2014","unstructured":"Fried LF, Emanuele N, Zhang JH. Combined angiotensin inhibition in diabetic nephropathy. N Engl J Med. 2014;370:779.","journal-title":"N Engl J Med"},{"key":"336_CR33","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870\u20138.","journal-title":"N Engl J Med"},{"key":"336_CR34","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"336_CR35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"KDOQI","year":"2012","unstructured":"KDOQI. Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60:850\u201386.","journal-title":"Am J Kidney Dis"},{"key":"336_CR36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","volume":"24","author":"DL Jennings","year":"2007","unstructured":"Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med. 2007;24:486\u201393.","journal-title":"Diabet Med"},{"key":"336_CR37","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","volume":"346","author":"H Makani","year":"2013","unstructured":"Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360.","journal-title":"BMJ"},{"key":"336_CR38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","journal-title":"N Engl J Med"},{"key":"336_CR39","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jacc.2013.10.050","volume":"63","author":"MZ Molnar","year":"2014","unstructured":"Molnar MZ, Kalantar-Zadeh K, Lott EH, et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol. 2014;63:650\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"336_CR40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659\u201363.","journal-title":"Arch Intern Med"},{"key":"336_CR41","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCULATIONAHA.108.829176","volume":"119","author":"SR Preis","year":"2009","unstructured":"Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119:1728\u201335.","journal-title":"Circulation"},{"key":"336_CR42","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/ndt\/gfh408","volume":"19","author":"WY Leung","year":"2004","unstructured":"Leung WY, So WY, Tong PC, et al. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant. 2004;19:2519\u201325.","journal-title":"Nephrol Dial Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-016-0336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T05:52:08Z","timestamp":1589694728000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-016-0336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,21]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1186\/s12882-016-0336-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,21]]},"article-number":"135"}}